Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure

Leukemia remains incurable partly due to difficulties in reaching and maintaining therapeutic drug concentrations in the target tissues and cells. Next-generation drugs targeted to multiple cell checkpoints, including the orally active venetoclax (Bcl-2 target) and zanubrutinib (BTK target), are eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, James, Wu, Yan, Mu, Qingxin, Li, Xinyan, Ho, Rodney J. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051515/
https://www.ncbi.nlm.nih.gov/pubmed/36986876
http://dx.doi.org/10.3390/pharmaceutics15031016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051515/
https://www.ncbi.nlm.nih.gov/pubmed/36986876
http://dx.doi.org/10.3390/pharmaceutics15031016

Ejemplares similares